Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis
- PMID: 20034758
- DOI: 10.1016/j.biopha.2009.04.039
Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis
Abstract
Prostaglandin E(2) (PGE(2)) and prostaglandin E (EP) receptor signaling pathways have been implicated in the promotion of tumor growth and angiogenesis. However, little is known about their roles in lymphangiogenesis during tumor development. The present study evaluates whether endogenous PGE(2) exhibits a critical role in tumor-associated lymphangiogenesis. Treatment of male C57BL/6 mice with a cyclooxygenase-2 inhibitor, celecoxib, for seven days resulted in a 52.4% reduction in tumor size induced by subcutaneous injection of murine Lewis lung cells. Celecoxib treatment down-regulated the expression of vascular endothelial growth factor receptor (VEGFR)-3 in stromal tissues by 73.9%, and attenuated expression of podoplanin, a marker for lymphatic endothelial cells. To examine the role of host PGE receptor signaling, we tested four kinds of EP receptor knockout mice. At Day 7 after tumor cell implantation, EP3 receptor knockout mice, but not EP receptor knockout mice lacking EP1, EP2, or EP4, exhibited a 53.3% reduction in tumor weight, which was associated with a 74.5% reduction in VEGFR-3 mRNA expression in tumor stromal tissues. At Day 14, VEGFR-3 expression in EP3-/- mice remained significantly lower than that of their wild-type (WT) counterparts. The expression of VEGF-C in the tumor stromal tissues in EP3-/- mice were also reduced by 22.1% (Day 7) and 44.1% (Day 14), respectively. In addition, the level of immunoreactive podoplanin in the tumor tissues from EP3-/- mice was less than that of WT. These results suggest that host EP3 receptor signaling regulates tumor-associated lymphangiogenesis by up-regulating expression of VEGF-C and its receptor, VEGFR-3, in tumor stromal tissues. Host EP3 blockade together with COX-2 inhibition may be a novel therapeutic strategy to suppress tumor-associated lymphangiogenesis.
2009 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth.Biochem Biophys Res Commun. 2009 May 15;382(4):720-5. doi: 10.1016/j.bbrc.2009.03.094. Epub 2009 Mar 24. Biochem Biophys Res Commun. 2009. PMID: 19318087
-
Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.Arterioscler Thromb Vasc Biol. 2011 May;31(5):1049-58. doi: 10.1161/ATVBAHA.110.222356. Epub 2011 Feb 10. Arterioscler Thromb Vasc Biol. 2011. PMID: 21311040
-
Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation.Biomed Pharmacother. 2010 Feb;64(2):93-100. doi: 10.1016/j.biopha.2009.04.034. Epub 2009 Oct 17. Biomed Pharmacother. 2010. PMID: 20015609
-
Pathways targeting tumor lymphangiogenesis.Clin Cancer Res. 2006 Dec 1;12(23):6865-8. doi: 10.1158/1078-0432.CCR-06-1800. Clin Cancer Res. 2006. PMID: 17145802 Review.
-
[Molecular biology of prostaglandin E receptors--expression of multi-function by PGE receptor subtypes and isoforms].Nihon Rinsho. 1998 Jul;56(7):1813-8. Nihon Rinsho. 1998. PMID: 9702058 Review. Japanese.
Cited by
-
The Roles of Non-Coding RNAs in Tumor-Associated Lymphangiogenesis.Cancers (Basel). 2020 Nov 6;12(11):3290. doi: 10.3390/cancers12113290. Cancers (Basel). 2020. PMID: 33172072 Free PMC article. Review.
-
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.Oncotarget. 2012 Aug;3(8):893-906. doi: 10.18632/oncotarget.593. Epub 2012 Aug 19. Oncotarget. 2012. PMID: 23097685 Free PMC article. Review.
-
Immunological significance of alternative splicing prognostic signatures for bladder cancer.Heliyon. 2022 Feb 19;8(2):e08994. doi: 10.1016/j.heliyon.2022.e08994. eCollection 2022 Feb. Heliyon. 2022. PMID: 35243106 Free PMC article.
-
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.BMC Cancer. 2018 Apr 16;18(1):431. doi: 10.1186/s12885-018-4286-9. BMC Cancer. 2018. PMID: 29661238 Free PMC article.
-
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?Br J Pharmacol. 2015 Nov;172(22):5239-50. doi: 10.1111/bph.13331. Epub 2015 Oct 26. Br J Pharmacol. 2015. PMID: 26377664 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous